|
| Human Envelop VLP Control (LTP10150) |
|
| LTP10150 |
|
| 100ug |
|
|
$226 In stock |
| VLPs are formed by spontaneous interaction between one or more viral structural capsid proteins to form the final structure. VLPs are structurally and visually similar to live viruses but lack either a complete virus genome or lack the entire virus genome[1]. The envelop VLP control is pure viral protein particle structure without the displayed proteins, which can be used as control for the activity assay of the envelope VLP display proteins. |
| Recombinant Human Envelop VLP Control is expressed from Expi293. Human Envelop VLP Control is formed by self-assembly of envelop/capsid proteins from viruses, which is pure viral protein particle structure without the displayed proteins. Human Envelop VLP Control can be used as isoytype control for VLPs displaying membrane proteins in various applications. |
|
| Envelop VLP Control |
|
| Human |
|
| 0 |
|
| 0 |
|
| 0 |
|
| 0 |
|
| 0 |
|
| Expi293 |
|
| > 95% as determined by HPLC |
|
| Less than 1EU per ug by the LAL method. |
|
| Lyophilized from 0.22 um filtered solution in PBS (pH 7.4). Normally 8% trehalose is added as a protectant before lyophilization. |
|
| Reconstituted protein stable at -80 C for 12 months, 4 C for 1 week. Use a manual defrost freezer and avoid repeated freeze-thaw cycles. |
|
| Shipped at ambient temperature. |
|
| Centrifuge tubes before opening. Reconstituting to a concentration of more than 100 ug/ml is recommended. Dissolve the lyophilized protein in distilled water. |
|
|  |
